Dow Down, AIM Immunotech Up

All three major indices fell today.

The NASDAQ fell 768.11 points.

The DOW fell 327.11 points.

The S&P fell 91.39 points.

Technology stocks and growth‑oriented shares led the market lower as investors reacted to rising oil prices and ongoing geopolitical tensions in the Middle East, which continued to weigh on sentiment and push risk assets downward. Pressure in energy markets contributed to inflation concerns, prompting broader selling across multiple sectors including financials, industrials, and consumer‑related companies.

The sharp decline in the S&P 500 suggested that selling activity was not limited to a single segment of the market, reflecting pervasive caution among traders and portfolio managers. Investors also remained attentive to upcoming economic data and Federal Reserve communications for further clues about the path of monetary policy and inflationary pressures as the Federal Reserve opted to keep rates steady this session.

Analysts noted that broader macroeconomic uncertainty, including the potential for sustained higher oil prices and geopolitical risk spillovers, has contributed to a risk‑off market tone.

Investors will continue watching upcoming economic reports and corporate developments later this week for further signals about the economy and financial markets' directions.

All this as AIM Immunotech shares rose 0.31 points to end the day at $1.02 per share. The company's shares surged following a significant intellectual property development. The company announced final approval in Japan for a patent covering its experimental therapy Ampligen in combination with checkpoint inhibitors, a move that strengthens its positioning in the oncology space. The firm also indicated plans to pursue orphan-drug designation in Japan for pancreatic cancer treatment, a signal of potential regulatory and commercial momentum.